Agarwala SS, Neuberg D, Park Y, Kirkwood JM (2004) Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer 100:1692–1698

CAS  Article  Google Scholar 

Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautes-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L et al (2014) Trial watch: toll-like receptor agonists in oncological indications. Oncoimmunology 3:e29179

Article  Google Scholar 

Benvenuti F (2016) The dendritic cell synapse: a life dedicated to T cell activation. Front Immunol 7:70

Article  Google Scholar 

Chang LS, Leng CH, Yeh YC, Wu CC, Chen HW, Huang HM, Liu SJ (2014) Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy. Mol Cancer 13:60

Article  Google Scholar 

Fernandez S, Palmer DR, Simmons M, Sun P, Bisbing J, McClain S, Mani S, Burgess T, Gunther V, Sun W (2007) Potential role for Toll-like receptor 4 in mediating Escherichia coli maltose-binding protein activation of dendritic cells. Infect Immun 75:1359–1363

CAS  Article  Google Scholar 

Franklin C, Livingstone E, Roesch A, Schilling B, Schadendorf D (2017) Immunotherapy in melanoma: Recent advances and future directions. Eur J Surg Oncol 43:604–611

CAS  Article  Google Scholar 

Fu HW (2014) Helicobacter pylori neutrophil-activating protein: From molecular pathogenesis to clinical applications. World J Gastroenterol 20:5294–5301

Article  Google Scholar 

Gajewski TF, Schreiber H, Fu YX (2013) Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 14:1014–1022

CAS  Article  Google Scholar 

Hong X, Dong T, Hu J, Yi T, Li W, Zhang Z, Lin S, Niu W (2013) Synergistical toll-like receptors activated dendritic cells induce antitumor effects against carcinoembryonic antigen-expressing colon cancer. Int J Colorectal Dis 28:25–33

Article  Google Scholar 

Huen AO, Rook AH (2014) Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma. Curr Opin Oncol 26:237–244

CAS  Article  Google Scholar 

Iribarren K, Bloy N, Buque A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R et al (2016) Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology 5:e1088631

Article  Google Scholar 

Kang QZ, Duan GC, Fan QT, Xi YL (2005) Fusion expression of Helicobacter pylori neutrophil-activating protein in E.coli. World J Gastroenterol 11:454–456

CAS  Article  Google Scholar 

Kidner TB, Morton DL, Lee DJ, Hoban M, Foshag LJ, Turner RR, Faries MB (2012) Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. J Immunother 35:716–720

CAS  Article  Google Scholar 

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25:402–408

CAS  Article  Google Scholar 

Martorelli D, Muraro E, Merlo A, Turrini R, Rosato A, Dolcetti R (2010) Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer. Int Rev Immunol 29:371–402

CAS  Article  Google Scholar 

Mempel TR, Bauer CA (2009) Intravital imaging of CD8+ T cell function in cancer. Clin Exp Metastasis 26:311–327

Article  Google Scholar 

Mikulandra M, Pavelic J, Glavan TM (2017) Recent findings on the application of toll-like receptors agonists in cancer therapy. Curr Med Chem 24:2011–2032

CAS  Article  Google Scholar 

Narayan R, Nguyen H, Bentow JJ, Moy L, Lee DK, Greger S, Haskell J, Vanchinathan V, Chang PL et al (2012) Immunomodulation by imiquimod in patients with high-risk primary melanoma. J Invest Dermatol 132:163–169

CAS  Article  Google Scholar 

Redelman-Sidi G, Glickman MS, Bochner BH (2014) The mechanism of action of BCG therapy for bladder cancer–a current perspective. Nat Rev Urol 11:153–162

CAS  Article  Google Scholar 

Riggs P (2000) Expression and purification of recombinant proteins by fusion to maltose-binding protein. Mol Biotechnol 15:51–63

CAS  Article  Google Scholar 

Rodriguez-Cerdeira C, Carnero Gregorio M, Lopez-Barcenas A, Sanchez-Blanco E, Sanchez-Blanco B, Fabbrocini G, Bardhi B, Sinani A, Guzman RA (2017) Advances in Immunotherapy for Melanoma: a comprehensive review. Mediators Inflamm 2017:3264217

Article  Google Scholar 

Sanlorenzo M, Vujic I, Posch C, Dajee A, Yen A, Kim S, Ashworth M, Rosenblum MD, Algazi A et al (2014) Melanoma immunotherapy. Cancer Biol Ther 15:665–674

Article  Google Scholar 

Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S (2018) Melanoma Lancet 392:971–984

Article  Google Scholar 

Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69:7–34

Article  Google Scholar 

Sisti A, Sisti G, Oranges CM (2014) Topical treatment of melanoma skin metastases with imiquimod: a review. Dermatol Online J 21:14

Google Scholar 

Smith M, Garcia-Martinez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L (2018) Trial Watch: Toll-like receptor agonists in cancer immunotherapy. Oncoimmunology 7:e1526250

Article  Google Scholar 

Vacchelli E, Eggermont A, Sautes-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L (2013) Trial Watch: Toll-like receptor agonists for cancer therapy. Oncoimmunology 2:e25238

Article  Google Scholar 

Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautes-Fridman C, Tartour E, Zitvogel L, Kroemer G (2012) Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncoimmunology 1:894–907

Article  Google Scholar 

Wahl RU, Braunschweig T, Ghassemi A, Rubben A (2016) Immunotherapy with imiquimod and interferon alfa for metastasized Merkel cell carcinoma. Curr Oncol 23:e150–e153

CAS  Article  Google Scholar 

Wang T, Liu X, Ji Z, Men Y, Du M, Ding C, Wu Y, Liu X, Kang Q (2015) Antitumor and immunomodulatory effects of recombinant fusion protein rMBP-NAP through TLR-2 dependent mechanism in tumor bearing mice. Int Immunopharmacol 29:876–883

CAS  Article  Google Scholar 

Weigelin B, Krause M, Friedl P (2011) Cytotoxic T lymphocyte migration and effector function in the tumor microenvironment. Immunol Lett 138:19–21

CAS  Article  Google Scholar 

Yang H, Wang B, Wang T, Xu L, He C, Wen H, Yan J, Su H, Zhu X (2014) Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis. PLoS ONE 9:e109980

Article  Google Scholar